Fig. 2

Ferrichrome exerted anti-tumor effects but not the anti-inflammatory effects in an in vivo animal model. Ferrichrome (5 mg/kg) was administered via intraperitoneal injection to AOM-DSS carcinogenesis model mice for 69 days. The tumor size in the ferrichrome-treated model mice was significantly reduced a without any marked change in the body weight (b). A Western blot analysis showed that the accumulation of cleaved caspase-3 and PARP was significantly higher in the ferrichrome-treated group than in the control group (c). However, 5 mg/kg of ferrichrome administered trans-anally did not improve the colon length d or the expression of inflammatory cytokines (TNFα, IL1β and IFNγ) e in a DSS-colitis model. *p < 0.05 by a one-way ANOVA followed by Ryan’s post hoc test (a). *p < 0.05 by Student’s t-test (b, d, e). The error bars show the standard deviation (S.D.)